Amyris_(company)

Amyris, Inc.

Amyris, Inc.

American biotechnology company

Amyris, Inc. is a synthetic biotechnology and renewable chemical company headquartered in Emeryville, California. Amyris serves the specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals markets.[3]

Quick Facts Company type, Traded as ...

History

Amyris was founded in 2003.[4] The company owns three brands, Biossance and Pipette, for beauty and skincare, and Purecane, a sugar substitute. The company went public on NASDAQ on September 28, 2010 (AMRS).[5]

In November 2011, Amyris acquired Lansing, Michigan-based renewable chemicals and products company, Draths Corporation, for $7 million in stock.[6] ATEL Capital Group acquired a stake in Amyris in December 2011.[7] In January 2016, the company received an investment from the Bill & Melinda Gates Foundation's Strategic Innovation Fund to support the development of antimalarial medication based on semi-synthetic artemisinin.[8] In April 2019, the company raised $34-million in private placement of its common stock and warrants. The funding round was led by Foris Ventures and Dr. Wei-wu He, General Partner of Emerging Technology Partners, LLC, a life sciences-focused venture fund.[9]

Biossance, the skincare brand from Amyris, was recognized as Digital Innovator of the Year at the WWD Beauty Inc Awards in 2019.[10]

In 2020, Amyris received Bonsucro's Chain of Custody Certification, ensuring that the sustainability claims along the sugarcane supply chain are traceable from farmer to end user.[11] During the COVID-19 pandemic, the company collaborated with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine.[12]

On August 9, 2023, Amyris filed for Chapter 11 bankruptcy protection and announced it will shut down its consumer brands amongst selling itself.[13] The company was delisted from Nasdaq and added to the OTC Markets.

References

  1. [1]
    "Amyris Annual Report - SEC filings".
  2. [2]
    "Amyris profile".
  3. [3]
    "Amyris Inc - Company Profile". Bloomberg.com.
  4. [4]
    Brodwin, Erin. "After a kick-start from Bill Gates, a Silicon Valley company aims to be the 'Intel Inside' of the $200 billion sweetener and skincare market". Business Insider. Retrieved 2023-03-21.
  5. [5]
    "Amyris, Inc. Chief Executive Officer to Ring the NASDAQ Stock Market Closing Bell". www.nasdaq.com. Retrieved 2020-06-30.
  6. [6]
    Riddell, Lindsay (November 16, 2011). "Amyris buys chemicals-maker Draths". San Francisco Business Journal.
  7. [7]
    Hilleman, Jeryl; Choksi, Paritosh K. (2011-12-23). "Amyris 2011 10-K Ex 4.07 Warrant to Atel". Securities and Exchange Commission. Archived from the original on 2023-12-24. Retrieved 2023-12-24.
  8. [8]
    "Amyris". Bill & Melinda Gates Foundation Strategic Innovation Fund. Archived from the original on 2023-12-24. Retrieved 2023-12-24.
  9. [9]
    Coons, Rebecca (April 29, 2019). "Amyris raises $34 million as it pursues skin care, sweeteners, and CBD | Nuu". Biofuels Digest. Nuu Media.
  10. [10]
    Writer (December 17, 2019). "WWD Beauty Inc Names Biossance Brand Digital Innovator Of The Year". markets.businessinsider.com.
  11. [11]
    Staff. "Amyris' Sugarcane Is Traceable". HAPPI.
  12. [12]
    "Amyris and The Infectious Disease Research Institute Enter into Exclusive License for Novel RNA Vaccine Platform, Beginning with COVID-19 Vaccine". Cision. 2020-10-20. Archived from the original on 2023-12-24.
  13. [13]
    "Amyris files for Chapter 11 bankruptcy protection in Delaware". Bloomberg Law. August 9, 2023. Retrieved August 10, 2023.
Share this article:

This article uses material from the Wikipedia article Amyris_(company), and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.